Literature DB >> 31797039

Comparison of intermittent and consecutive balneological outpatient treatment (hydrotherapy and peloidotherapy) in fibromyalgia syndrome: a randomized, single-blind, pilot study.

Rıza Eröksüz1, Fatma Begüm Erol Forestier2, Fatih Karaaslan3, Romain Forestier2, Halim İşsever4, Nergis Erdoğan5, Müfit Zeki Karagülle5, Arif Dönmez6.   

Abstract

To compare the efficacy of intermittent and consecutive balneological outpatient treatment (hydrotherapy and peloidotherapy) in fibromyalgia syndrome (FMS). A parallel 1:1, single-blind, pilot study was performed. Patients were recruited from musculoskeletal disorders outpatient clinic. Eligible participants were patients aged 18-60, diagnosed as FMS according to ACR 2010 criteria. They were randomly assigned to either consecutive or intermittent treatment groups. Both groups received 20 min of full body immersion in a tap water pool at 38-39 °C and 30 min of mud pack application on the back region at 45 °C. Delivery of the treatment was five times weekly during 2 weeks in consecutive group and two times weekly during 5 weeks in intermittent group. The primary outcomes were pain intensity and the number of patients achieving a minimal clinically important difference (MCID) on Fibromyalgia Impact Questionnaire (FIQ) at the 1st month after the completion of the treatment. Statistical analyses were based on intention to treat method. The assessing physician was blinded. Pain intensity significantly decreased in all post-treatment evaluations of both groups (except after treatment in the intermittent group). There was no significant difference between the groups. MCID for FIQ was achieved in 6 (24%) patients in the consecutive group and 12 (48%) in the intermittent group at the 1st month. There was no statistical difference in the secondary judgment criteria. The consecutive and intermittent deliveries of balneological outpatient treatment (hydrotherapy and peloidotherapy) seem to have similar effects on the clinical status of patients with FMS.

Entities:  

Keywords:  Balneotherapy; Fibromyalgia syndrome; Hydrotherapy; Intermittent balneotherapy; Peloidotherapy

Mesh:

Year:  2019        PMID: 31797039     DOI: 10.1007/s00484-019-01838-3

Source DB:  PubMed          Journal:  Int J Biometeorol        ISSN: 0020-7128            Impact factor:   3.787


  29 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

Review 2.  A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology.

Authors:  Christoph Gutenbrunner; Tamas Bender; Pedro Cantista; Zeki Karagülle
Journal:  Int J Biometeorol       Date:  2010-06-09       Impact factor: 3.787

3.  Is balneotherapy effective for fibromyalgia? Results from a 6-month double-blind randomized clinical trial.

Authors:  Antonella Fioravanti; Patrizia Manica; Roberto Bortolotti; Gabriele Cevenini; Sara Tenti; Giuseppe Paolazzi
Journal:  Clin Rheumatol       Date:  2018-05-05       Impact factor: 2.980

4.  The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire.

Authors:  S Sarmer; S Ergin; G Yavuzer
Journal:  Rheumatol Int       Date:  2000-12       Impact factor: 2.631

5.  The effect of balneotherapy on osteoarthritis. Is an intermittent regimen effective?

Authors:  Moshe Tishler; Oskar Rosenberg; Ofer Levy; Iris Elias; Mirit Amit-Vazina
Journal:  Eur J Intern Med       Date:  2004-04       Impact factor: 4.487

6.  Intermittent balneotherapy at the Dead Sea area for patients with knee osteoarthritis.

Authors:  Gilad Sherman; Lior Zeller; Avital Avriel; Michael Friger; Marco Harari; Shaul Sukenik
Journal:  Isr Med Assoc J       Date:  2009-02       Impact factor: 0.892

7.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.

Authors:  F Wolfe; H A Smythe; M B Yunus; R M Bennett; C Bombardier; D L Goldenberg; P Tugwell; S M Campbell; M Abeles; P Clark
Journal:  Arthritis Rheum       Date:  1990-02

Review 8.  Crenobalneotherapy for limb osteoarthritis: systematic literature review and methodological analysis.

Authors:  Romain Forestier; Alain Françon
Journal:  Joint Bone Spine       Date:  2007-12-31       Impact factor: 4.929

Review 9.  EULAR revised recommendations for the management of fibromyalgia.

Authors:  G J Macfarlane; C Kronisch; L E Dean; F Atzeni; W Häuser; E Fluß; E Choy; E Kosek; K Amris; J Branco; F Dincer; P Leino-Arjas; K Longley; G M McCarthy; S Makri; S Perrot; P Sarzi-Puttini; A Taylor; G T Jones
Journal:  Ann Rheum Dis       Date:  2016-07-04       Impact factor: 19.103

10.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02
View more
  4 in total

1.  Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia.

Authors:  Francesco Pazzi; José Carmelo Adsuar; Francisco Javier Domínguez-Muñoz; Miguel Angel García-Gordillo; Narcis Gusi; Daniel Collado-Mateo
Journal:  Healthcare (Basel)       Date:  2020-11-30

2.  Peloids as Thermotherapeutic Agents.

Authors:  Francisco Maraver; Francisco Armijo; Miguel Angel Fernandez-Toran; Onica Armijo; Jose Manuel Ejeda; Iciar Vazquez; Iluminada Corvillo; Silvia Torres-Piles
Journal:  Int J Environ Res Public Health       Date:  2021-02-18       Impact factor: 3.390

3.  Therapeutic Patient Education for Fibromyalgia during Spa Therapy: The FiETT Randomized Controlled Trial.

Authors:  Philippe Ducamp; Patrick Sichère; Hermine Gayum; Karine Dubourg; Christian-François Roques; Valérie Journot
Journal:  Int J Environ Res Public Health       Date:  2022-04-11       Impact factor: 4.614

4.  Italian and Japanese public attention toward balneotherapy in the COVID-19 era.

Authors:  Maria Chiara Maccarone; Hiroharu Kamioka; Sara Cheleschi; Sara Tenti; Stefano Masiero; Sinan Kardeş
Journal:  Environ Sci Pollut Res Int       Date:  2021-06-29       Impact factor: 4.223

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.